Prof. Martinelli will speak about new drugs in the treatment of acute leukemias, starting from mechanisms of actions of the compounds and explaining strategies for clinical research.

Venetoclax is a bcl-2 inhibitor that is entering in the therapy of AML. The use of venetoclax will be explored with particular attention to combination with purine and pyrimidine analogs and metabolism.

Ponatinib is a pan TKI with particular activity on BCR-ABL1 fusion protein, VEGF and FLT3, and a high number of collateral activity on immunogenic cell death and environment. Ponatinib is able to protect against the emergence of BCR-ABL1 mutations. Ponatinib was used in new-onset and relapse-refractory Ph+ ALL. The use of ponatinib may be further expanded in Ph-like/3C-UP ALL and in subcategories of AML.

Gilteritinib is an FLT3, AXL, and ALK inhibitor with single-agent activity in R/R AML. Gilteritinib multikinase inhibition and differentiation effects will be explored, together with combination with chemotherapy.

MDM2 and Menin inhibition are appealing strategies in the treatment of predefined subsets of AML, preliminary laboratory data will be presented.